Johnson & Johnson (NYSE:JNJ) today reported third-quarter results that topped the consensus forecast, with international pharma sales up 2.6% or 9.0% operationally.
Drugs fueling growth include Stelara (ustekinumab), Darzalex (daratumumab), Tremfya (guselkumab), Xarelto (rivaroxaban) and Erleada (apalutamide).
J&J licensed Darzelex from Genmab. The drug won FDA approval in 2015 for patients with previously treated multiple myeloma. Darzalex now has eight FDA-approved indications.
Another drug fueling growth was the atypical antipsychotic Invega Hafyera (paliperidone palmitate), which is the first six-month injectable for schizophrenia on the U.S. market.
Sales declined for the biologic Remicade (infliximab) and the immune-mediated inflammatory disease therapy Imbruvica (ibrutinib).
MedTech business sales increased more than 2%.
The New Brunswick, New Jersey-based company posted profits of $4.5 billion, or $1.68 per share in the quarter. It pulled in sales of $23.8 billion for the three months ended Sept. 30, 2022. That marked a 21.6% bottom-line gain on sales growth of 1.9%.
Adjusted to exclude one-time items, earnings per share were $2.48. That beat Wall Street expectations by 7¢, while analysts looked for sales of $23.3 billion.
Despite the positive financials, the company is likely to trim its staff in the near future, according to a WSJ article featuring input from Chief Financial Officer Joseph Wolk.